JPRN-jRCT1031190033Completed未知
Clinical investigation on the effects of biological agents on asthma and search for biological markers - Clinical effects and biomarkers of biological agents on asthma
MORI AKIO0 sites12 target enrollmentStarted: May 28, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 12
Study Overview
Brief Summary
Biomarkers associated with the effects of biological agents were aimed by the current investigation, which was unfortunately suspended due to the quit of the supporting grant. Further enrollment or follow up of the patients was not possible. Biomarkers associated with the biological agents would greatly ease economical and clinical needs in this field.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 12age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •1) Asthma patients diagnosed based on Japanese Asthma Prevention and Management Guideline 2018 who are older than 12 years old
- •2) Either anti-IgE antibody (Zorea), anti-IL-5 antibody (Nucala), or anti-IL-5 receptor antibody (Facenra) is going to be administered.
- •3) Written informed consent from the patients or the legal gardian is obtained.
Exclusion Criteria
- •1) Those patients who can not be taken blood sample
- •2) Those patients who were judged not suitable for the entry to this investigation be the responsible doctor
Investigators
Similar Trials
Completed
Phase 1
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).Head and Neck Squamous Cell CarcinomaNCT03022409AstraZeneca21
Recruiting
Unknown
Prospective study of biomarkers and pharmacological characteristics for patients with metastatic lung tumorsmetastatic lung tumorJPRN-UMIN000053045Keio University550
Not yet recruiting
Not Applicable
Evaluation of the Efficacy of Novel Biomarkers in Predicting Clopidogrel Resistance in Patients with Ischemic StrokeIschemic StrokeTIA (Transient Ischemic Attack)Clopidogrel ResistanceNCT06753149Nanjing First Hospital, Nanjing Medical University800
Recruiting
Not Applicable
Exploratory study of biomarkers for therapeutic efficacy and immune-related adverse events of immune checkpoint inhibitorsAll cancer types indicated for immune checkpoint inhibitorJPRN-UMIN000043798Kumamoto University400
Completed
Phase 1
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue SarcomaSoft Tissue SarcomaNCT02783599Eli Lilly and Company51